Scarica l'app Stockscreener
2.51
4.58%
0.11
Dopo l'orario di chiusura:
2.49
-0.02
-0.80%
Precedente Chiudi:
$2.40
Aprire:
$2.52
Volume 24 ore:
2.53M
Relative Volume:
0.34
Capitalizzazione di mercato:
$695.43M
Reddito:
-
Utile/perdita netta:
$-225.14M
Rapporto P/E:
-1.2806
EPS:
-1.96
Flusso di cassa netto:
$-192.27M
1 W Prestazione:
+1.62%
1M Prestazione:
+5.46%
6M Prestazione:
+248.32%
1 anno Prestazione:
+443.88%
Intervallo 1D:
$2.42
$2.545
Intervallo di 1 settimana:
$2.37
$2.59
Portata 52W:
$0.3546
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Nome
Invivyd Inc
Settore
Industria
Telefono
(781) 819-0080
Indirizzo
209 CHURCH STREET, NEW HAVEN
Confronta IVVD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
2.51 | 664.96M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-22 | Iniziato | BTIG Research | Buy |
| 2025-11-25 | Downgrade | D. Boral Capital | Buy → Hold |
| 2025-10-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-26 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Invivyd Inc Borsa (IVVD) Ultime notizie
Why Invivyd Inc. stock is trending among retail traders2025 Earnings Surprises & Free Reliable Trade Execution Plans - ulpravda.ru
Invivyd reports 25% growth in Q4 PEMGARDA revenue to $17.2 million - Investing.com Australia
Invivyd Reports Strong PEMGARDA Growth and Advances VYD2311 - TipRanks
Invivyd, Inc. Reports Preliminary Q4 2025 Revenue of $17.2 Million and Announces Key Clinical Developments - Quiver Quantitative
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - The Manila Times
Press Release: Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights - 富途牛牛
Aug Gainers: Why Heiwa Real Estate Co Ltd HZJ stock appears on watchlistsDividend Hike & Growth Focused Entry Reports - moha.gov.vn
Invivyd Inc. | Latest News & Innovations - shababeek.org
BTIG initiates Invivyd (IVVD) coverage, cites VYD2311’s superior market potential over Pemgarda - MSN
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311’s Superior Market Potential Over Pemgarda - Insider Monkey
BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda - Finviz
Invivyd (NASDAQ:IVVD) Trading Down 3.7%Here's Why - MarketBeat
Is Invivyd Inc. stock supported by strong fundamentalsChart Pattern Recognition & Minimal Risk High Reward - bollywoodhelpline.com
Does Invivyd’s (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? - Yahoo Finance
BTIG Reiterates Invivyd (IVVD) Buy Recommendation - Nasdaq
BTIG Research Upgrades Invivyd (NASDAQ:IVVD) to Strong-Buy - MarketBeat
Invivyd granted FDA fast track status for COVID therapy - MSN
FDA grants fast track designation for Invivyd’s COVID antibody By Investing.com - Investing.com Nigeria
Invivyd begins phase 3 trial of COVID prevention antibody VYD2311 By Investing.com - Investing.com Nigeria
US OPEN: Markets wobble amid low volumes and resilient GDP (23.12.2025) - XTB.com
Is Invivyd’s (IVVD) Index Debut Quietly Reframing Its Long-Term Biotech Positioning? - simplywall.st
Invivyd wins FDA fast track tag for COVID drug (IVVD:NASDAQ) - Seeking Alpha
Invivyd Says Vaccine-Alternative Antibody to Prevent COVID Gets FDA Fast Track Designation; Phase 3 Trial Launched - marketscreener.com
Invivyd’s COVID Antibody VYD2311 Receives FDA Fast Track - TipRanks
FDA grants fast track designation for Invivyd’s COVID antibody - Investing.com India
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - The Manila Times
Invivyd announces initiation of DECLARATION clinical trial, a phase 3 placebo-controlled pivotal study of VYD2311, a vaccine-alternative antibody to prevent Covid-19 - marketscreener.com
Invivyd stock rises after FDA grants Fast Track designation for COVID antibody - Investing.com Canada
Invivyd, Inc. Earns Fast Track Designation for COVID Antibody - TradingView — Track All Markets
Invivyd rises as drugmaker starts late-stage trial for COVID prevention antibody - TradingView — Track All Markets
Invivyd begins phase 3 trial of COVID prevention antibody VYD2311 - Investing.com
FDA puts COVID prevention shot alternative from Invivyd on Fast Track - Stock Titan
New antibody shot aims to offer vaccine-alternative protection from COVID - Stock Titan
Invivyd (IVVD): Assessing Valuation After S&P Biotechnology Select Industry Index Inclusion - Yahoo Finance
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
Invivyd announces proposed public offering of common stock - MSN
Invivyd, Inc. (IVVD): Advancing RSV antibody VBY329 amid analyst downgrade - MSN
Invivyd (NASDAQ:IVVD) Shares Gap UpShould You Buy? - MarketBeat
BTIG Initiates Invivyd at Buy With $10 Price Target - marketscreener.com
Invivyd stock initiated with Buy rating at BTIG on COVID antibody potential - Investing.com India
Invivyd stock initiated with Buy rating at BTIG on COVID antibody potential By Investing.com - Investing.com South Africa
BTIG Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - Nasdaq
Invivyd, Inc.(NasdaqGM: IVVD) added to S&P Biotechnology Select Industry Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to NASDAQ Biotechnology Index - marketscreener.com
Invivyd, Inc. (NASDAQ:IVVD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Invivyd Inc (IVVD) Stock News & Articles - 24/7 Wall St.
Aug Sentiment: Is Invivyd Inc. stock undervalued vs historical averagesWeekly Investment Summary & Smart Swing Trading Alerts - Улправда
How Invivyd Inc. stock reacts to Fed rate cutsProduct Launch & Technical Pattern Alert System - ulpravda.ru
Is Invivyd Inc. stock a good choice for value investorsJuly 2025 Gainers & Long Hold Capital Preservation Plans - Улправда
Is Invivyd Inc. stock undervalued vs historical averages2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
How analysts rate Invivyd Inc. stock todayWeekly Stock Report & High Accuracy Investment Signals - DonanımHaber
Invivyd Inc Azioni (IVVD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):